SCHEMBL3245100

SCHEMBL3245100

CCc1c(C(=O)O)ccc(O)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 1/20 0.49
SELL P14151 1/20 0.41
SELP P16109 1/20 0.41
HTT P42858 1/20 0.39
DRD2 P14416 1/20 0.38
CSNK2A1 P68400 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
TPMT P51580 4/20 0.38
POLB P06746 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 1/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
KLKB1 P03952 1/20 0.37
CTSB P07858 1/20 0.37
MMP9 P14780 1/20 0.37
DNMT1 P26358 1/20 0.37
DNMT3B Q9UBC3 1/20 0.37
DNMT3L Q9UJW3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369498 0.88 TDP1 (0.50) TDP1MAPTSELLSELPHTT
SCHEMBL4216080 0.86 TDP1 (0.49) TDP1MAPTSELLSELPHTT
Hydrochloric Acid SCHEMBL6437034 0.86 TDP1 (0.47) TDP1MAPTHTTPOLBHSD17B10
SCHEMBL25232693 0.85 TDP1 (0.47) TDP1MAPTSELLSELPHTT
SCHEMBL3365334 0.85 TDP1 (0.47) TDP1MAPTSELLSELPHTT
SCHEMBL3370741 0.85 TDP1 (0.47) TDP1MAPTSELLSELPHTT
SCHEMBL1940681 0.85 HMGCR (0.47) TDP1MAPTHTTDRD2POLB
SCHEMBL28665839 0.84 PPARA (0.46) TDP1MAPTPPARGPPARAGABRP
SCHEMBL11895245 0.83 TDP1 (0.46) TDP1MAPTSELLSELPHTT
Hydrochloric Acid SCHEMBL7999971 0.83 NNMT (0.38) TDP1MAPTHTTDRD2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118678895-A Article for an aerosol delivery system and method of manufacturing an article for an aerosol delivery system 尼科创业贸易有限公司 2024-09-20 CN claimed
CN-118401125-A Assembly for use in or as an article of an aerosol provision system 尼科创业贸易有限公司 2024-07-26 CN claimed
CN-118265464-A Aerosol generating material 尼科投资贸易有限公司 2024-06-28 CN claimed
CN-118159148-A Aerosol-generating composition comprising nicotine and an acid or nicotine salt 莱战略控股公司 2024-06-07 CN claimed
CN-117813019-A Assembly for an article for use in an aerosol provision system 尼科创业贸易有限公司 2024-04-02 CN claimed
CN-117750893-A Assembly for an article for use in an aerosol provision system 尼科创业贸易有限公司 2024-03-22 CN claimed
CN-117561005-A Assembly for an article for use in an aerosol provision system 尼科创业贸易有限公司 2024-02-13 CN claimed
CN-117098469-A Assembly for an article for use in an aerosol provision system 尼科创业贸易有限公司 2023-11-21 CN claimed
CN-113897244-B Preparation method and application of cigarette spice 深圳市兰科植物保护研究中心 2023-10-27 CN claimed
CN-113811198-B Aerosol supply system 尼科创业贸易有限公司 2023-06-23 CN claimed
CN-113795153-A Methods and compositions for improving the taste of sugarless cola soda water and other beverages 格雷戈里·阿哈罗尼安 2021-12-14 CN claimed
CN-122094577-A Component for aerosol supply article 2026-05-26 CN disclosed
CN-122094581-A Compatibility of consumables with aerosol provision devices 2026-05-26 CN disclosed
CN-122074723-A Method of manufacturing an aerosol generator 2026-05-26 CN disclosed
CN-122070060-A Article for or as an aerosol supply system 尼科创业贸易有限公司 2026-05-19 CN disclosed
WO-2004050080-A1 TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES VELA PHARMACEUTICALS, INC. (US) 2004-06-17 WO disclosed
WO-2004050616-A2 TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES VELA PHARMACEUTICALS, INC. (US) 2004-06-17 WO disclosed
US-20040106602-A1 Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines VELA ACQUISITION CORPORATION 2004-06-03 US disclosed
US-20040106601-A1 Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines VELA ACQUISITION CORPORATION 2004-06-03 US disclosed
US-6638928-B1 Benzodiazepines administered for irritable bowel syndrome and nonulcer dyspepsia. VELA PHARMACEUTICALS, INC. 2003-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106602-A1 Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines LTB4R2, LTB4R, PTGER4 TDP1 4276/4885MAPT 2791/4885SELL 718/4885
US-20040106601-A1 Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines OPRL1, OPRD1, GABRR1 TDP1 4352/4885MAPT 4329/4885SELL 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.